CoChat

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies

Open access

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Colorectal cancers that display reduced sensitivity to EGFR inhibition and strong IGF2 overexpression can be effectively treated by dual EGFR/IGF2 blockade.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.3010445

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 117

Metadata

Authors
Zanella, E. R., Galimi, F., Sassi, F., Migliardi, G., Cottino, F., Leto, S. M., Lupo, B., Erriquez, J., Isella, C., Comoglio, P. M., Medico, E., Tejpar, S., Budinská, E., Trusolino, L., & Bertotti, A.
Affiliations
  • Candiolo Cancer Institute (IT)
  • Department of Oncology, University of Torino Medical School, 10060 Candiolo, Torino, Italy.
  • Universitair Ziekenhuis Leuven (BE)
  • Institute of Biostatistics and Analyses, Masaryk University, 611 37 Brno, Czech Republic.
  • Istituto Nazionale Biostrutture e Biosistemi (IT)
Corresponding author
  • Zanella, Eugenia R.
  • Galimi, Francesco
  • Sassi, Francesco
  • Trusolino, Livio
  • Bertotti, Andrea
Venue
Science Translational Medicine
Published
2015-01-28
Volume
7
Issue
272
Pages
272ra12-272ra12
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W2144987077
Cited by
117
References
47
Citations by year
2026: 4 · 2025: 3 · 2024: 5 · 2023: 10 · 2022: 9 · 2021: 14 · 2020: 13 · 2019: 12 · 2018: 13 · 2017: 14 · 2016: 13 · 2015: 7
FWCI
6.84
Type
journal article
Language
en
Open access
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Lirias (submittedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Funders
  • American Association for Cancer Research (12-20-16-BERT)
  • Ministero dell'Universita e della Ricerca
  • Associazione Italiana per la Ricerca sul Cancro
  • AIRC Investigator (14205, 11852)
  • European Regional Development Fund
  • Fondo per gli Investimenti della Ricerca di Base_Futuro in Ricercaq
  • Fondazione Piemontese per la Ricerca sul Cancro-ONLUS
  • State Budget of the Czech Republic-RECAMO (CZ.1.05/2.1.00/03.0101)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
Keywords
insulin-like growth factor II, colorectal cancer, anti-EGFR therapy, cetuximab, stable disease, patient-derived xenografts, IGF2 overexpression, combination therapy, predictive biomarkers, treatment resistance
MeSH terms
Cetuximab, Animals, Antineoplastic Agents, Clinical Trials as Topic, Exons, Humans, Immunohistochemistry, Insulin-Like Growth Factor II, Ligands, Mutation, Neoplasm Transplantation, Biomarkers, Tumor, Colorectal Neoplasms, Drug Resistance, Neoplasm, Mice, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. https://app.cochat.ai/papers/10.1126/scitranslmed.3010445
The paper
Zanella, E. R., Galimi, F., Sassi, F., Migliardi, G., Cottino, F., Leto, S. M., Lupo, B., Erriquez, J., Isella, C., Comoglio, P. M., Medico, E., Tejpar, S., Budinská, E., Trusolino, L., & Bertotti, A. (2015). IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.3010445

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.